Two Sigma Advisers LP raised its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 38,200 shares of the company's stock after buying an additional 8,900 shares during the period. Two Sigma Advisers LP owned about 0.11% of Harrow worth $1,282,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC bought a new position in shares of Harrow in the 4th quarter valued at $78,000. AlphaQuest LLC grew its stake in shares of Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after buying an additional 2,889 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Harrow during the 4th quarter valued at approximately $214,000. Finally, Maridea Wealth Management LLC acquired a new position in Harrow in the fourth quarter valued at $222,000. 72.76% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. HC Wainwright lifted their price target on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th. B. Riley reduced their price target on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.
Check Out Our Latest Report on HROW
Harrow Stock Performance
Shares of HROW traded up $0.17 on Wednesday, reaching $29.51. The company's stock had a trading volume of 329,927 shares, compared to its average volume of 498,579. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock's 50 day simple moving average is $25.32 and its two-hundred day simple moving average is $30.23. The stock has a market capitalization of $1.08 billion, a P/E ratio of -31.39 and a beta of 0.41. Harrow, Inc. has a 12-month low of $16.87 and a 12-month high of $59.23.
Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Research analysts forecast that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.
Harrow Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
